baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

GILEAD SCIENCES DL-,001/ US3755581036 /

2024-12-20 9:55:11 PM	Chg. +0.840	Volume	Bid9:59:57 PM	Ask9:59:57 PM	Market Capitalization	Dividend Y.	P/E Ratio
88.750EUR	+0.96%	615 Turnover: 54,207	88.740Bid Size: 169	88.800Ask Size: 169	110.62 bill.EUR	-	-

GlobeNewswire 08-27 Alex Bastian joins Memo Therapeutics AG as VP Commercial Strategy

GlobeNewswire 08-08 HOOKIPA Pharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights

GlobeNewswire 08-08 Assembly Biosciences Reports Second Quarter 2024 Financial Results and Recent Updates

GlobeNewswire 08-08 Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2024 Financial Results

GlobeNewswire 08-06 MacroGenics Provides Update on Corporate Progress, Second Quarter 2024 Financial Results

GlobeNewswire 08-05 89bio Reports Second Quarter 2024 Financial Results and Corporate Updates

GlobeNewswire 08-05 89bio Appoints Charles McWherter, Ph.D., to its Board of Directors

GlobeNewswire 08-01 Merus Announces Financial Results for the Second Quarter 2024 and Provides Business Update

GlobeNewswire 07-23 ACTG Presents Data Analysis at AIDS 2024 Showing Association between Elevated Risk of Cardiovascular...

GlobeNewswire 07-15 Assembly Biosciences Presents New Preclinical Data Highlighting Investigational Helicase-Primase Inh...

GlobeNewswire 07-08 Memo Therapeutics AG appoints Paul Carter as Chairperson

GlobeNewswire 07-04 Burns McClellan Mourns the Passing of Founder and CEO, Lisa Burns

GlobeNewswire 07-01 HOOKIPA Pharma Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment o...

GlobeNewswire 07-01 Vera Therapeutics Announces Appointment of Industry Veteran David L. Johnson as Chief Operating Offi...

GlobeNewswire 06-28 Ensho Therapeutics Launches with Phase 2-Ready Oral α4β7 Inhibitor for Inflammatory Bowel Disease

GlobeNewswire 06-26 Neurona Therapeutics Appoints Dr. Nadia Agopyan as Senior Vice President of Regulatory Affairs

GlobeNewswire 06-26 Oruka Therapeutics Announces Key Additions to Leadership Team and Board of Directors

TeleTrader 06-20 US opens mostly higher after labor, housing data

GlobeNewswire 06-18 Assembly Biosciences Doses First Participant in Phase 1b Clinical Trial Evaluating Next-Generation C...

GlobeNewswire 06-17 Assembly Biosciences Announces $12.6 Million in Equity Financings

GlobeNewswire 06-10 Assembly Biosciences Doses First Participant in Phase 1a/b Clinical Trial of Herpes Simplex Virus He...

GlobeNewswire 05-22 Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL Congres...

GlobeNewswire 05-14 Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results

GILEAD SCIENCES DL-,001/ US3755581036 /

If you wish to receive reply to your feedback, please provide your email address.